Please assess the completion status of the following clinical trial:

Trial Title: Single-Arm Study To Evaluate The Efficacy and Safety of Valoctocogene Roxaparvovec in Hemophilia A Patients (BMN 270-301)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Males ≥ 18 years of age with hemophilia A and residual FVIII levels ≤ 1 IU/dL as evidenced by medical history, at the time of signing the informed consent.~2. Must have been on prophylactic FVIII replacement therapy for at least 12 months prior to study entry.~3. Treated/exposed to FVIII concentrates or cryoprecipitate for a minimum of 150 exposure days (EDs).~4. No previous documented history of a detectable FVIII inhibitor, and results from a Bethesda assay or Bethesda assay with Nijmegen modification of less than 0.6 Bethesda Units (BU) on 2 consecutive occasions at least one week apart within the past 12 months.~Exclusion Criteria:~1. Detectable pre-existing antibodies to the adeno-associated virus 5 (AAV5) capsid.~2. Any evidence of active infection or any immunosuppressive disorder, except for HIV infection~3. Any evidence of active infection or any immunosuppressive disorder, including HIV infection (effective as of Protocol Amendment 3)~4. Significant liver dysfunction.~5. Prior liver biopsy showing significant fibrosis.~6. Evidence of any bleeding disorder not related to hemophilia A.~7. Platelet count of \< 100 x 10\^9/L.~8. Creatinine ≥ 1.5 mg/dL.~9. Liver cirrhosis of any etiology as assessed by liver ultrasound.~10. Chronic or active hepatitis B.~11. Active Hepatitis C.~12. Active malignancy, except non-melanoma skin cancer.~13. History of hepatic malignancy.~14. History of arterial or venous thromboembolic events.~15. Known inherited or acquired thrombophilia, including conditions associated with increased thromboembolic risk, such as atrial fibrillation.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- valoctocogene roxaparvovec Open Label (Type: EXPERIMENTAL): Single administration of valoctocogene roxaparvovec at a dose of 6E13 vg/kg

Based on this trial design, predict the completion outcome and termination type (if applicable).